With the rising prevalence of antimicrobial resistance, the treatment success of standard
triple therapy has recently declined to unacceptable levels (ie, 80% or less) in most …

At present, the best rescue therapy for Helicobacter pylori (H. pylori) infection following
failure of first-line eradication remains unclear. The Maastricht V/Florence Consensus …

This review summarizes important studies regarding H. pylori therapy published from April
2013 to April 2014. The main themes that emerge are assessing the efficacy of standard …

Background Traditional standard triple therapy for Helicobacter pylori (H. pylori) infection
(proton pump inhibitor-clarithromycin-amoxicillin) can easily be converted to non-bismuth …

Hybrid therapy is a novel two-step treatment achieving a high eradication rate for
Helicobacter pylori infection. Currently, whether this new therapy achieves a higher …

Helicobacter pylori (H. pylori) is an important major cause of peptic ulcer disease and gastric
malignancies such as mucosa-associated lymphoid tissue lymphoma and gastric …

Triple therapy, consisting of two antibiotics, clarithomycin and amoxicillin or metronidazole in
combination with a proton pump inhibitor (PPI) has become the first-line option for infection …

Background. None of the currently used anti‐Helicobacter pylori drug regimens cures the
infection 100%, and cure results still vary considerably. The present article reviews the …

The efficacy of triple therapy for Helicobacter pylori infection has dramatically declined over
the last decade, largely related to increasing clarithromycin resistance rates. From a …

Helicobacter pylori (H. pylori) is a well-known human pathogen that plays an essential role
in the pathogenesis of chronic gastritis, peptic ulcer disease, and gastric malignancies …